<DOC>
	<DOC>NCT00511433</DOC>
	<brief_summary>The primary purpose of this study is to evaluate the effects of the nomegestrol acetate-estradiol (NOMAC-E2) combined oral contraceptive (COC) on ovarian function.</brief_summary>
	<brief_title>Effects on Ovarian Function of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing DRSP/EE (292003)(COMPLETED)(P05723)</brief_title>
	<detailed_description />
	<mesh_term>Megestrol</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Contraceptives, Oral</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Drospirenone</mesh_term>
	<mesh_term>Contraceptives, Oral, Combined</mesh_term>
	<criteria>Willing to use COC for at least 6 cycles. 18 35 years of age at screening. Body Mass Index (BMI) of &gt;/= 17 and &lt;/= 35. Good physical and mental health. Willing to use condoms as the sole contraceptive method during screening cycle and 1 posttreatment cycle. Willing to give informed consent. Contraindications for contraceptive steroids (general). Additional contraindications (renal, hepatic or adrenal insufficiency). Breastfeeding. Present use (or use within 2 months prior to start of the trial medication) of the following drugs: phenytoin, barbiturates, primidone, carbamazepine, oxcarbazepine, topiramate, felbamate, rifampicin, nelfinavir, ritonavir, griseofulvin, ketoconazole, sex steroids (other than pre and post treatment contraceptive method) and herbal remedies containing Hypericum perforatum (St. John's Wort). Administration of any other investigational drugs and/or participation in another clinical trial within 2 months prior to the start of the trial medication or during the trial period. Abnormal cervical smear at screening, or documentation of an abnormal smear performed within 6 months before screening. Clinically relevant abnormal laboratory result at screening as judged by the investigator.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>